Innate Pharma SA (IPH.PA)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|55||2016||Chairman of the Supervisory Board|
|58||2016||Chairman of the Executive Board, Chief Executive Officer|
|56||2009||Independent Vice Chairman of the Supervisory Board|
|39||2016||Chief Financial Officer, Executive Vice President, Member of the Executive Committee|
|57||2014||Executive Vice President in charge of Operations, Member of the Executive Committee, Chief Development Officer|
- BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN
- BRIEF-Reg-Innate Pharma Aacr 2018, New Preclinical Data Further Support Ongoing Programs
- BRIEF-Innate Pharma Announces Its Partner Medimmune Expands Colorectal Cancer Patient Cohort In A Phase I Trial
- BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi
- BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4 Million Euros